Overview
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
Status:
Recruiting
Recruiting
Trial end date:
2021-12-01
2021-12-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Five Eleven Pharma, Inc.
Criteria
Inclusion Criteria:- histologically confirmed prostate cancer. known or suspected bone metastases referred
for a clinical [99mTc]MDP scan
Exclusion Criteria:
- Estimated creatinine clearance (GFR) < 30 mL/min (calculated), history of
hyperparathyroidism, • Inability to tolerate imaging procedures in the opinion of an
investigator or treating physician, • Any current medical condition, illness, or
disorder as assessed by medical record review and/or self-reported that is considered
by a physician investigator to be a condition that could compromise participant safety
or successful participation in the study